TrialDrugs2022
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Sahil Khanna et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
184 papers cite itlatest 60 shown
this paperpooled ittrialcites it